Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2018

01-09-2018 | Original Article

Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan

Authors: Kazuhiro Kitajima, Koya Nakatani, Kazushige Yamaguchi, Masatoyo Nakajo, Atsushi Tani, Mana Ishibashi, Keiko Hosoya, Takahiro Morita, Takayuki Kinoshita, Hayato Kaida, Yasuo Miyoshi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2018

Login to get access

Abstract

Purpose

The purpose of this study was to evaluate therapeutic response to neoadjuvant chemotherapy (NAC) and predict breast cancer recurrence using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).

Materials and methods

Fifty-nine breast cancer patients underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and after NAC prior to planned surgical resection. Pathological complete response (pCR) of the primary tumor was evaluated using PERCIST, while effects of clinicopathological factors on progression-free survival (PFS) were examined using log-rank and Cox methods.

Results

Fifty-six patients and 54 primary tumors were evaluated. Complete metabolic response (CMR), partial metabolic response, stable metabolic disease, and progressive metabolic disease were seen in 45, 7, 3, and 1 patients, respectively, and 43, 7, 3, and 1 primary tumors, respectively. Eighteen (33.3%) of the 54 primary tumors showed pCR. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PERCIST to predict pCR were 100% (18/18), 30.6% (11/36), 41.9% (18/43), 100% (11/11), and 53.7% (29/54), respectively. An optimal percent decrease in peak standardized uptake value for a primary tumor corrected for lean body mass (SULpeak) of 84.3% was found to have a sensitivity of 77.8% (14/18), specificity of 77.8% (28/36), PPV of 63.6% (14/22), NPV of 87.5% (28/32), and accuracy of 77.8% (42/54). Seven (12.5%) of the 56 patients developed recurrent disease (median follow-up 28.1 months, range 11.4–96.4 months). CMR (p = 0.031), pCR (p = 0.024), and early TNM stage (p = 0.033) were significantly associated with longer PFS.

Conclusion

PERCIST is useful for predicting pathological response and prognosis following NAC in breast cancer patients. However, FDG-PET/CT showed a tendency toward underestimation of the residual tumor, and relatively low specificity and PPV of PERCIST showed that a combination of other imaging modalities would still be needed to predict pCR.
Literature
1.
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.CrossRefPubMed
2.
Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) Protocol B-18. Cancer. 2002;95:681–95.CrossRefPubMed
3.
Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008;26:786–90.CrossRefPubMed
4.
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:78–85.CrossRef
5.
Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005;23:7098–104.CrossRefPubMed
6.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
7.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.CrossRefPubMedPubMedCentral
8.
Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology. 2012;263:53–63.CrossRefPubMed
9.
Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, et al. Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:32–40.CrossRefPubMed
10.
Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer. 2013;13:271–9.CrossRefPubMed
11.
Choi EK, Yoo IR, Kim SH, Park SY, O JH, Kang BJ. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI. Acta Radiol. 2018;59:41–9.CrossRefPubMed
12.
Tőkés T, Kajáry K, Szentmártoni G, Lengyel Z, Györke T, Torgyík L, et al. Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer. Breast Cancer. 2017;24:137–46.CrossRefPubMed
13.
Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0. Eur J Radiol. 2018;101:65–71.CrossRefPubMed
14.
Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, Nakamura S, et al. Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 2008;15:5–7.CrossRefPubMed
15.
Sheikhbahaei S, Trahan TJ, Xiao J, Taghipour M, Mena E, Connolly RM, et al. FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies. Oncologist. 2016;21:931–9.CrossRefPubMedPubMedCentral
16.
Huppe AI, Mehta AK, Brem RF. Molecular breast imaging: a comprehensive review. Semin Ultrasound CT MR. 2018;39:60–9.CrossRefPubMed
17.
Collarino A, de Koster EJ, Valdés Olmos RA, de Geus-Oei LF, Pereira Arias-Bouda LM. Is technetium-99m sestamibi imaging able to predict pathologic nonresponse to neoadjuvant chemotherapy in breast cancer? A meta-analysis evaluating current use and shortcomings. Clin Breast Cancer. 2018;18:9–18.CrossRefPubMed
18.
Collarino A, Valdés Olmos RA, van der Hoeven AF, Pereira Arias-Bouda LM. Methodological aspects of 99mTc-sestamibi guided biopsy in breast cancer. Clin Transl Imaging. 2016;4:367–76.CrossRefPubMedPubMedCentral
19.
Kalinyak JE, Berg WA, Schilling K, Madsen KS, Narayanan D, Tartar M. Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:260–75.CrossRefPubMed
20.
Noritake M, Narui K, Kaneta T, Sugae S, Sakamaki K, Inoue T, et al. Evaluation of the response to breast cancer neoadjuvant chemotherapy using 18F-FDG positron emission mammography compared with whole-body 18F-FDG PET: a prospective observational study. Clin Nucl Med. 2017;42:169–75.CrossRefPubMed
Metadata
Title
Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan
Authors
Kazuhiro Kitajima
Koya Nakatani
Kazushige Yamaguchi
Masatoyo Nakajo
Atsushi Tani
Mana Ishibashi
Keiko Hosoya
Takahiro Morita
Takayuki Kinoshita
Hayato Kaida
Yasuo Miyoshi
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4008-1

Other articles of this Issue 10/2018

European Journal of Nuclear Medicine and Molecular Imaging 10/2018 Go to the issue

Original Article

18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients

Original Article

Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT

Editorial

Molecular imaging and molecular diagnostics: two sides of the same coin?

Guidelines

Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline

Letter to the Editor

Optimal method for measuring baseline metabolic tumor volume in DLBCL patients: are statistical agreements of SUV ≥2.5 satisfactory?

Original Article

Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies